ALGS Aligos Therapeutics, Inc.
Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 1799448 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY122.2%
TTM net income YoY23.3%
TTM EPS YoY52.3%
Revenue 3-yr CAGR1.8%
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin-1,244.2%
Net margin-1,137.2%
FCF margin—
EBITDA margin-1,223.5%
Returns
ROE-159.5%
ROA-84.5%
ROIC (approx.)-1,147.1%
Asset turnover0.07x
Leverage & solvency
Liabilities / assets76.0%
Debt / equity0.00x
Current ratio1.77x
Interest coverage—
Cash quality & payout
Operating cash flow / net income1.03x
Accruals ratio2.7%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | $2.19M | $3.61M |
| R&D expense | $69.45M | $70.27M |
| SG&A expense | $20.72M | $22.83M |
| Operating income | -$87.98M | -$89.15M |
| Pretax income | -$23.88M | -$130.88M |
| Income tax | $314,000 | $331,000 |
| Net income | -$24.19M | -$131.21M |
| EBITDA | -$87.06M | -$88.13M |
| EPS (basic) | -2.45 | -20.94 |
| EPS (diluted) | -2.45 | -20.94 |
| Weighted avg. shares (diluted) | 9.88M | 6.26M |
| Banking | ||
| Net interest income | $2.20M | $1.70M |
| Balance sheet | ||
| Cash & equivalents | $18.30M | $37.11M |
| Short-term investments | $59.54M | $19.94M |
| Current assets | $82.86M | $62.14M |
| PP&E, net | $1.87M | $2.36M |
| Total assets | $88.53M | $70.09M |
| Current liabilities | $21.23M | $21.74M |
| Total liabilities | $34.99M | $99.07M |
| Shareholders' equity | $53.55M | -$28.97M |
| Shares outstanding | 6.18M | 3.86M |
| Cash flow statement | ||
| Operating cash flow | -$82.50M | -$80.74M |
| Capital expenditure | — | $130,000 |
| Free cash flow | — | -$80.87M |
| Investing cash flow | -$37.83M | -$18.28M |
| Financing cash flow | $101.64M | $355,000 |
| Depreciation & amortization | $930,000 | $1.03M |
| Stock-based compensation | $5.04M | $8.45M |
Free plan shows the latest 2 periods; Pro shows all 7 🔒
· This company does not report gross profit in XBRL.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.